Sarcomatous intrahepatic cholangiocarcinoma

Summary

Sarcomatous intrahepatic cholangiocarcinoma (MONDO:0004451) is a disease. A subtype of intrahepatic cholangiocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	sarcomatous intrahepatic cholangiocarcinoma
Mondo ID	MONDO:0004451
DOID	DOID:8072
NCIT	C41620
UMLS	C1519184
MedGen	275403
GARD	0024012
Is cancer (heuristic)	no

Also known as: intrahepatic cholangiocarcinoma with extensive sarcomatous changes · sarcomatoid intrahepatic cholangiocarcinoma

Disease family

This is a subtype of intrahepatic cholangiocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › biliary tract cancer › bile duct cancer › intrahepatic bile duct cancer › intrahepatic cholangiocarcinoma › sarcomatous intrahepatic cholangiocarcinoma

Related subtypes (5): hilar cholangiocarcinoma, mucinous intrahepatic cholangiocarcinoma, cholangiolocellular carcinoma, signet ring cell intrahepatic cholangiocarcinoma, perihilar intrahepatic cholangiocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.